Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer

Area of Science:

• Oncology
• Molecular Biology
• Precision Medicine

Background:

• NTRK gene fusions are oncogenic drivers across diverse cancer types.
• Tropomyosin receptor kinase (TRK) proteins are targeted by novel therapies.
• Larotrectinib (Vitrakvi®) is an FDA-approved TRK inhibitor demonstrating efficacy.

Purpose of the Study:

• To review the role of NTRK gene fusions in oncogenesis.
• To discuss the therapeutic potential of TRK inhibitors like larotrectinib.
• To outline methods for detecting NTRK gene fusions in cancer patients.

Main Methods:

• Review of scientific literature on NTRK gene fusions and TRK inhibitors.
• Analysis of diagnostic approaches for NTRK gene fusion detection.
• Summary of clinical trial data for larotrectinib in TRK fusion cancers.

Main Results:

• NTRK gene fusions are confirmed oncogenic drivers in various malignancies.
• Larotrectinib exhibits significant efficacy and a favorable safety profile in TRK fusion-positive cancers.
• Multiple detection methods are available, including FISH, RT-PCR, IHC, and NGS.

Conclusions:

• Targeting NTRK gene fusions with TRK inhibitors offers a promising precision therapy strategy.
• Accurate detection of NTRK gene fusions is crucial for patient selection.
• Identifying patients with TRK fusion-positive cancers optimizes treatment outcomes.